cRGD-functionalized mPEG-PLGA-PLL nanoparticles for imaging and therapy of breast cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 22763223.
- Also identified by DOI 10.1016/j.biomaterials.2012.06.008.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cyclic peptide (arginine-glycine-aspartic-glutamic-valine acid, cRGD)-modified monomethoxy (polyethylene glycol)-poly (D,L-lactide-co-glycolide)-poly (L-lysine) nanoparticles (mPEG-PLGA-PLL-cRGD NPs) with antitumor drug Mitoxantrone (DHAQ) or fluorescence agent Rhodamine B (Rb) encapsulated in their interior were prepared. The remarkable features of the mPEG-PLGA-PLL-cRGD NPs are the effective improvement for the cytotoxicity and uptake of the cell in vitro, and the significant enhancement of delivery ability for DHAQ or Rb in vivo. As a consequence, an excellent therapeutic efficiency for cancer is obtained, demonstrating the mPEG-PLGA-PLL-cRGD NPs play a key role in enhancing cancer therapeutic efficiency.
Medical subject headings
- Breast Neoplasms
- Drug Carriers
- Nanoparticles
- Peptides, Cyclic
- Polyesters
- Polyethylene Glycols
- Polylysine